The demethylating agents 5-azacytidine and 5-aza-2 0 -deoxycytidine (DAC) have been shown to induce differentiation and inhibit growth of leukemic myeloid cells at low concentrations. However, the effect of DAC in changing the differentiation and proliferation behavior of normal human myeloid progenitors has rarely been investigated. Therefore, we established an in vitro model of normal hematopoietic differentiation, using CD34 þ cells from mobilized peripheral blood, to study proliferation and colony formation, expression of several myeloid maturation markers and of the inhibitor of cyclin-dependent kinases p15/INK4b. Upon DAC treatment, cell growth was significantly decreased in a dose-dependent manner, without an increase in cytotoxicity. DAC treatment also resulted in a substantial increase of lysozyme-positive cells, which could be enhanced by G-CSF, a modest increase of myeloperoxidase þ and CD15
Introduction
DNA methylation is a major epigenetic mechanism controlling tissue-and development-specific gene regulation. Methylation of myeloid-specific genes such as myeloperoxidase (MPO), Lysozyme (LZM), and colony-stimulating factor (CSF) receptors is decreased concomitant with normal hematopoietic differentiation. [1] [2] [3] [4] [5] In cancer cells, it is a common observation that aberrant methylation represses transcription of tumor suppressor genes such as p15/INK4B and p16/INK4A. 6 A recent study suggested that DNA methylation of the p15 promoter region is associated with proliferation rather than differentiation of normal human myeloid progenitor cells. 7 Conversely, the Sphase-specific demethylating agents 5-azacytidine and 5-aza-2 0 -deoxycytidine (DAC) have shown a striking effect the induction of differentiation of murine embryonic fibroblasts into myocytes, adipocytes and chondrocytes, 8 and a moderate differentiationinducing activity on myeloid leukemic cell lines. 6, [9] [10] [11] [12] [13] [14] [15] [16] It has been shown that exposure of human bone marrow CD34 þ cells to DAC and the histone deacetylase (HDAC) inhibitor trichostatin (TSA) resulted in a significant expansion of early progenitor cells (CD34 þ /CD90 þ ), which retained repopulating capacity in nonobese diabetic mice with severe combined immunodeficiency disease (NOD/SCID). 17 These data point to a role of demethylating agents, particularly in combination with an HDAC inhibitor, in altering the fate of primitive hematopoietic progenitor cells and in maintaining their primitive phenotype. Furthermore, injection of murine neural stem cells treated with DAC and TSA, either into blastocysts or irradiated adult recipients, led to long-term multilineage bone marrow reconstitution, indicating that epigenetic modification can release the commitment of the neural stem cells (Mü ller AM, Wü rzburg, Germany, personal communication). However, a potential role of DAC in inducing differentiation of normal myeloid progenitors has not yet been investigated. To this end, we established an in vitro model of normal hematopoietic differentiation modulated by demethylation, using CD34 þ cells from mobilized peripheral blood as harvested in apheresis specimens (AP). We analyzed proliferation, viability, colony formation, expression of CD15, LZM, MPO and p15, as well as p15 DNA methylation for the effects of noncytotoxic doses of DAC.
Materials and methods

Patients and stem cell mobilization
In all, 22 patients and three healthy donors were studied (15 males, 10 females). Nine patients had a diagnosis of nonHodgkin's lymphoma (NHL), five had breast cancer, six multiple myeloma, one Ewing's sarcoma and one severe scleroderma. As reported previously, peripheral blood progenitor cells (PBPCs) were mobilized by chemotherapy plus granulocyte colonystimulating factor (G-CSF) in patients, or with G-CSF alone in healthy donors. [18] [19] [20] The patients were treated with standarddose VIP-E (etoposide (VP16) 500 mg/m 2 ). G-CSF (Filgrastim; Amgen, Munich, Germany) was started day (d) 7 after the chemotherapy cycle at daily subcutaneous (s.c.) injections of 5 mg/kg body weight (bw), continued until the end of apheresis. Healthy donors who were scheduled for stem cell transplantations were mobilized with 24 mg rhG-CSF/kg bw s.c. as published previously, 19 and PBPCs were collected beginning on d4. Apheresis was performed using a continuous flow cell separator (Spectra, Cobe BCT, Inc., Lakewood, CO, USA). The study was carried out under the guidelines of the ethical committee of the University of Freiburg and good clinical practice (GCP) guidelines. Informed written consent was obtained from each patient and donor.
CD34
þ cell isolation, purity and viability of CD34 þ cells CD34 þ immunoselection (CliniMACS, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) was performed according to the manufacturer's instructions and as described elsewhere. 21 Briefly, the PBPC apheresis product was washed with Dulbecco's phosphate-buffered saline (PBS) containing 1% (v/v) human serum albumin (DPBS-HSA). The washed cell pellet was resuspended into 100 ml with DPBS-HSA containing 7.5 ml of CliniMACS CD34 reagent (Miltenyi) and incubated for 30 min at room temperature (RT) under gentle agitation. After two further washing steps, nucleated cells were resuspended in 100-250 ml of DPBS-HSA, the bag was connected to the CliniMACS device and the clinical grade closed system automatically performed the CD34 þ cell selection. CD34-positive cells labeled with superparamagnetic iron-dextran particles conjugated to a CD34 antibody (QBEND 10) were captured in the magnetic separation unit. The purified cells were eluted and frozen in the presence of 7.5% dimethylsulfoxide and 4% HSA in PBS supplemented with 10 U/ml heparin (Liquemin, Roche, Grenzach, Germany). Aliquots of the CD34 þ fraction were analyzed for WBCs, CD34
þ and cell numbers, and colony-forming capacity. CD34 þ cells were stored in liquid nitrogen. All cell processing and storage steps were performed according to Good Manufacturing Practice guidelines. After thawing, CD34
þ cells were of a high purity (median 97.0%; range 80.9-98.4%; n ¼ 14) and viability (median 93.7%; range 83.5-99.0%; n ¼ 13).
Cell culture (short-term suspension culture) and DAC treatment Prior induction of cell division ('priming') of hematopoietic progenitors (which are mostly in the G0 state of the cell division cycle) may enhance the potential effect of DAC, which is an Sphase-specific drug. Therefore, as reported previously, 22 cells were expanded ('primed') by culturing 1-4 Â 10 4 cells/ml IMDM supplemented by 10% FCS and multiple cytokines in a 75 cm 2 Costar tissue culture flask (Corning) in a total volume of 10-20 ml. Initially, a three-factor cytokine cocktail consisting of 100 ng/ml IL-3, 100 ng/ml SCF, 100 ng/ml Flt3 was used, mainly for cell maintenance in ex vivo culture rather than for extensive cell expansion. 19 Later, for further cell expansion, a five-factor cocktail with the addition of TPO (50 ng/ml) and IL-6 (20 ng/ml) and serum-free medium was used. Since DAC has recently been shown to expand normal hematopoiesis of myelodysplastic syndrome (MDS) patients at low concentrations when given over 72 hours, we used three DAC pulses, given on d3-5 of ex vivo culture (Figure 1) . In selected experiments, G-CSF (10 ng/ ml) was added on d5 along with the last pulse of DAC. The cells were recovered on d7 of culture and enumerated by Trypan blue staining. To measure cell viability, the cells were stained with 2 mg/ml propidium iodide (PI) and analyzed on a flow cytometer FACSCalibur (BD). Additional assays were performed as described below.
Colony-forming assay
As reported previously, 23 5 Â 10 3 cells were cultured in 0.9% methylcellulose supplemented with Iscove's modified dulbecco's medium and 30% fetal calf serum plus recombinant human erythropoietin (1 U/ml), IL-3 (100 ng/ml), and G-CSF (100 ng/ml). Semisolid cultures were performed in duplicates. After 10-14 days of incubation, hematopoietic colonies were enumerated with an inverted microscope. Colonies of more than 50 cells were scored as myeloid (CFU-granulocyte-monocyte (CFU-GM)), erythroid (burst-forming unit-erythrocyte (BFU-E)) and multilineage colonies (CFU-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM)).
Flow-cytometric analyses
Flow-cytometric analyses were performed on the dual-laser flow cytometer FACSCalibur (BD) as described previously. 18 Briefly, cells were incubated with monoclonal antibodies labeled by fluorescein (FITC) and phycoerythrin (PE) for 20 min at 41C. After washing with PBS, cells were resuspended and analyzed on FACSCalibur. The following antibodies were used: control (for FITC and PE, BD), anti-CD15-PE (BD), anti-CD34-PE (BD), anti-MPO-FITC and anti-LZM-FITC (An Der Grub). Since MPO and LZM are intracellular pan-myeloid marker molecules, before staining with antibodies against these proteins, cells were permeabilized using Fix & Perm Cell Permeabilization kit (An Der Grub) according to the manufacturer's instruction. Data were analyzed by the Cell Quest program (BD).
Western blot
Total cellular protein was prepared by using a whole-cell protein lysis buffer. Protein was quantified by standard-curve method using Bradford reagent (Biorad). Total protein (50 mg) was separated on a 12% NuPAGE Bis-Tris gel (Invitrogen) and transferred to PVDF membranes (Hybond-P, Amersham Pharmacia Biotech). The membranes were blocked in 5% nonfat dried milk, 0.1% Tween-20 in PBS (MT-PBS) for 1 h at RT or overnight at 41C. Membranes were incubated with primary antibodies (1:500, c-20, rabbit anti-p15, Santa Cruz; 1:12000, rabbit-anti-actin, Sigma) for 1 h or overnight, and with secondary antibodies for one hour at RT. The membranes were then developed by an enhanced chemiluminescence system (Amersham Pharmacia Biotech). Antiactin was used as a loading control. The TGF-b-treated cell line HaCat was kindly provided by Dr N Fusenig at German Cancer Center, Heidelberg, used as a positive control for p15 protein.
Methylation analysis by bisulfite genomic sequencing
Bisulfite genomic sequencing was performed according to the established protocol. 24 In brief, 2 mg of DNA (isolated using standard protocols) was digested with EcoRI (Boehringer Mannheim, Indianapolis, IN, USA) and treated with sodium bisulfite for 16 h as described. Bisulfite-treated genomic DNA days of culture harvest G-CSF 10ng/ml Figure 1 Schematic representation of experimental design. Prior induction of cell division ('priming') of hematopoietic progenitors (which are mostly in the G0 state of the cell division cycle) enhances the effect of DAC which is an S-phase specific drug. Therefore, CD34
þ cells (490% in G0 phase) were primed from d0 to d3 in serum-free medium plus 100 ng/ml Flt3 þ 100 ng/ml SCF þ 50 ng/ml IL-3 þ 20 ng/ml IL-6 þ 50 ng/ml TPO; d3-5, decitabine treatment with three pulses of the indicated concentrations; d5, G-CSF priming; d7, cell harvest. DAC ¼ decitabine.
was amplified with primers for the 5 0 region of p15. Purified PCR products were subcloned using a TA cloning kit (Invitrogen, San Diego, CA, USA). Individual clones were grown and DNA was prepared using mini-prep kits (Qiagen). Up to 10 individual clones of each bisulfite preparation were subjected to automated sequencing in both directions using an ABI Sequencer (Foster City, CA, USA). The methylation status was expressed in percentage of methylated CpG islands divided by total CpG islands of these clones. The mean was calculated for the analysis. When more than two alleles showing variable hypermethylation were identical in a given experiment, these were excluded from the analysis to avoid the possibility of cloning artifacts.
Results
Dose-dependent growth inhibition of normal myeloid progenitor cells by DAC
CD34
þ cells are mostly in G0/G1 phase (490%), suggesting their quiescent status 25 (data not shown). In order to yield sufficient numbers of 'cycling' progenitor cells to incorporate DAC (which is S-phase specific), a short-term ex vivo suspension culture system was employed. With a three-factor cytokine cocktail containing Flt3, SCF and IL-3, a median cell expansion of 2.0-fold (range 0.4-8.7; n ¼ 7) was achieved after 7 days of culture. The addition of IL-6 and TPO in a serum-free medium led to significantly enhanced myeloid progenitor expansion (median cell expansion of 13.4-fold, range 1.7-23.8, n ¼ 18).
After priming CD34
þ cells for 72 h using this schedule, the cells were exposed to three daily pulses of the demethylating agent DAC, using low concentrations (from 10 to 100 nM) to avoid cytotoxic effects (Figure 1 ). Cells were harvested 48 h after the last pulse of DAC. As shown in Figure 2 , cell growth decreased in a dose-dependent manner upon treatment with DAC. DAC treatment did not result in a significant increase of PI-positive cells (data not shown). Although the PI staining is relatively insensitive to measure apoptosis, the observed growth-inhibitory effect of DAC was unlikely due to cytotoxicity or selection.
Change in the colony-forming potential of ex-vivo cultured CD34
þ cells treated with DAC
Following suspension culture, colony-forming assays revealed that, although CFU-GM increased somewhat on d7 of culture as compared to d0, total CFU/5000 cells decreased. This was mainly due to a substantial decrease of BFU-E on d7 as compared to d0 (Po0.01, n ¼ 13; Table 1 ). Interestingly, treatment with 10-100 nM DAC led to increased numbers of total CFU-GM and CFU as compared to control cells. Although such trends did not reach statistic significance, this increase in CFU occured be in a dose-dependent manner (Table 1) .
LZM expression of normal myeloid precursors is upregulated by DAC and enhanced by G-CSF
Since the growth-inhibitory effects of DAC may be associated with induction of cellular differentiation, we investigated the expression of the myeloid marker genes LZM, MPO and CD15 (all of which have CpG islands, which for LZM and MPO were shown to be more methylated in immature than in terminally differentiated myeloid cells). FACS analysis was used to quantitatively measure the expression of these proteins. Expression of LZM, MPO and CD15 was significantly upregulated upon suspension culture, indicating differentiation in addition to expansion of the myeloid progenitors (Figure 3a ). Upon treatment with DAC, MPO expression was moderately but reproducibly increased at higher DAC concentrations (Figure 3b ; median 15.4% MPO þ cells for control, 21.8% for 100 nM DAC-treated cells, P40.05, n ¼ 3). DAC also moderately enhanced CD15 expression in cultured myeloid cells (d0: median 2.2% CD15 þ cells d7: 33.2% for control cells, 40.1% for cells treated with 10 nM DAC, 38.3% for cells treated with 50 nM DAC, n ¼ 9); these results also were not statistically significant. In contrast, the number of LZM þ cells (described as percentages) increased significantly compared to control cells, with a modest but reproducible enhancement of expression (Figure 3b þ cells were subjected to ex vivo suspension culture as described in the text. On d3-5, DAC was added at various concentrations (0, 10, 50, 100 nM). On d7, cells were harvested to be enumerated after Trypan blue staining; only live cells were counted. *Po0.01, compared to control (no DAC-treated cells) at d7. p15/INK4b protein is strongly and rapidly induced with in vitro differentiation of normal CD34 þ cells
In normal myeloid progenitor cells, a lineage-and developmentspecific role in growth inhibition and differentiation has been proposed for the inhibitor of cyclin-dependent kinases (INK) p15/INK4b. 26 In myeloid leukemia and MDS, the CpG island of the p15 gene is frequently hypermethylated and silenced, and this inactivation, at least in transformed cells, is sensitive to demethylating agents. We asked whether expression of p15 protein correlated with the observed differentiation of CD34 þ cells cultured as described above. As shown in Figure 4 , no p15 protein was detected in CD34 þ cells before suspension culture. Interestingly, upon stimulation with serum-free medium and cytokines for 7 days, the p15 protein expression was strongly induced. No further induction was observed when cells were also treated with DAC (100 nM).
The p15 CpG island methylation status was also analyzed before and during myeloid differentiation by the quantitative bisulfite sequencing method. The CpG island was partially methylated in CD34 þ cells before culture (d0: median 73.7%, range 0-99.2%; n ¼ 7). The methylation status was independent of patient or donor age or whether cells were from healthy donors or patients (data not shown). Upon expansion in the absence of DAC, the overall change in methylation was not significant (median of 75.5% alleles were methylated, range 68.4-87.9%; n ¼ 7). Also, treatment with 100 nM DAC did not consistently result in a decrease in methylation (median degree of methylation 84.6%, range 42.4-89%; n ¼ 7), with only one individual exhibiting a strong decrease in methylation ( Figure 5 ). 3 and 4-6 , respectively) are shown. Note: Before suspension culture, no (lane 1) or only very weak expression (lane 4) of p15 is observed; however, upon differentiation after culture, robustly upregulated p15 expression was observed with (lanes 3 and 6, 100 nM for 3 pulses) or without DAC treatment (lanes 2 and 5). As loading control, b-actin (Sigma) was used in parallel, as shown in the lower panel.
Effect
Discussion
Compared to the dramatic increase in our present knowledge about genes being hypermethylated during development of neoplasia, 6 and effects of pharmacological reversal of this neoplasia-associated hypermethylator phenotype, relatively little is as yet known about the role of regulated methylation during normal myeloid differentiation and the effects of pharmacological methylation inhibition upon normal hematopoietic precursor cells. It has been shown that lineage-specific genes such as LZM and MPO, which are not expressed and whose CpG islands are methylated in primitive hematopoietic progenitor cells, become demethylated and activated during differentiation of these cells into the myeloid lineage. 5 However, very few studies have addressed the effects of demethylating agents such as azanucleosides on the in vitro differentiation, growth and colony formation of primitive hematopoietic progenitors. 7, 17 Therefore, the first aim of the present study was to establish an ex vivo model of cell differentiation of normal myeloid progenitor cells induced by the demethylating agent DAC. Our data demonstrate that, at low-to noncytotoxic concentrations, DAC induces a marked, dose-dependent inhibition of cell growth, changes in colony-forming potential indicative of differentiation and an increase in the expression of several differentiation-associated genes bearing CpG islands, in cytokine-expanded normal hematopoietic progenitor cells. This DAC effect was particularly evident for LZM expression and was enhanced by G-CSF.
A recent study illustrated that short-term exposure of bone marrow CD34 þ cells to DAC and TSA, or DAC alone, resulted in a substantial expansion of myeloid progenitors determined by phenotype (CD34 þ /CD90 þ ) and function both in vitro (CFU-GM and CFU-Mix) and in vivo (in NOD/SCID mice), suggesting an important role of DAC, at least in combination with an HDAC inhibitor, in the expansion of myeloid progenitors. 17 We observed only a 50% increase of total CFU and no significant increase of CD34 þ cells upon DAC treatment (Table 1, data not shown). This is most likely due to either the different concentrations of DAC used (10-100 nM versus 1 mM, with a higher degree of cytotoxicity in the other study), or, less likely, the different cell sources used (PB as compared to BM. 17 ). Out ex vivo culture was performed without EPO, which most likely contributed to the decreased numbers of BFU-E. Treatment with DAC at low dose (50 nM) slightly enhanced the forming of BFU-E. Although the difference is not significant, our data support a role of DAC in modifying the fate of erythroid progenitors. 17 DAC at a higher dose (100 nM) inhibited generation of BFU-E, indicating that DAC may be toxic to erythroid progenitors. 27 A second aim of these studies was to better understand the mechanism of growth regulation in this model. We thus analyzed the expression and methylation of the p15/INK4b gene. This gene is frequently repressed in myeloid leukemias and preleukemias (MDS) by promoter methylation, 6 but its role in normal hematopoiesis is not well understood. Upregulation of p15 during myeloid maturation was previously reported, 26, [28] [29] [30] and in a model of cytokine-expanded myeloid cells from cord blood cells p15 protein was first detectable at d21 of culture. 7 We now demonstrate that, at the conditions used, the p15 protein is already strongly induced after 7 days of ex-vivo culture, concomitant with the induction of myeloid differentiation. Additional DAC treatment did not further enhance p15 expression. This may be due to the already very strong effect of induction in response to cytokine-induced differentiation. Alternatively, promoter methylation of tumor suppressor genes in normal cells may not be as sensitive to the action of demethylating agents compared to hypermethylated areas in malignant cells (see below). Indirect evidence for this exists in microarray analyses of normal fibroblasts treated with DAC, which show very few changes in transcription compared to their malignant counterpart. 31 Also, the clinical observation of cytogenetic normalization, that is, clonal replacement of the leukemic cells with normal hematopoietic cells even with lowdose DAC treatment of elderly MDS patients, is clearly indicative of the differential sensitivity of normal compared to Figure 5 Methylation of p15 alleles suspension culture. Change of methylation status of the p15 gene (5 0 region) during myeloid differentiation is shown. Whole genomic DNA from untreated and 100 nM DAC-treated cells was modified by sodium bisulfite and thereafter amplified by PCR using specific primers for p15 CpG-rich region as reported previously 5 (data from two patients are given before and after: (a) patient #2; (b) patient #7). Methylation status of 21 CpG positions in the 5 0 region of the p15 gene is displayed. Each row represents a single cloned allele. K methylated CpG; J unmethylated CpG. DAC was given in three pulses at 100 nM.
Effect of 5-aza-2 0 -deoxycytidine on myeloid differentiation Y Guo et al leukemic progenitors to the growth-inhibitory and proapoptotic effects of this drug. 32 Of note, CD34 þ PBPCs mobilized by G-CSF treatment in our hands frequently showed at least partial methylation, which was overall not altered by ex-vivo differentiation and expansion and the DAC treatment used. This may also reflect that, in normal hematopoietic cells, regulation of p15 may not be as strictly dependent on the methylation status of the CpG islands as in their malignant counterparts. Alternatively, the high degree of expression noted after 7 days of culture may be driven from the remaining unmethylated alleles. Methylation of CD34 þ cells may differ depending on the cell source (unstimulated normal human bone marrow cells have been described as bearing a mostly unmethylated p15 promoter). 24, 33 We did not observe a systematic induction of p15 methylation following cytokine treatment of CD34 þ cells as reported by Sakashita et al., 7 perhaps due to different culture conditions, cytokines used, cell sources and timings. Our methylation data on p15 suggest that DAC at the low concentrations used in this model does not consistently decrease the methylation status of the p15 gene promoter of normal human PB myeloid progenitors. In contrast, DAC (at somewhat higher concentrations) clearly contributes to demethylation and expression of p15 in leukemic myeloid cells in vitro and in vivo 6 (Berg et al., submitted). However, our results on p15 protein expression, as well as a recent report by others, 34 indicate that p15 is regulated in a lineage-specific fashion in myeloid cells. Therefore, the role of p15 in normal myeloid differentiation warrants further investigation.
The observed induction of LZM expression with ex vivo culture and its enhancement with the addition of DAC is in line with our previous report of demethylation of this gene in normal hematopoietic cells, as assayed by Southern blot analysis. 1 Bisulfite sequencing of the LZM gene 5 0 region and CpG island, to address whether differential demethylation of the LZM and p15 occurs in these untransformed cells, might reveal a relative resistance of the p15 CpG island to demethylation in this cell type, as opposed to leukemic myeloid cells where p15 is readily demethylated with nanomolar concentrations of DAC (Berg et al., in preparation).
Taken together, these results indicate that DAC alters the growth and differentiation characteristics of normal myeloid progenitor cells during ex vivo expansion and differentiation. This model therefore appears suitable also for global analyses of gene methylation and expression profiling during lineagespecific maturation. Finally, that this demethylating agent, particularly in combination with an HDAC inhibitor, is able to expand primitive hematopoietic progenitors 17 may also partly explain the in vivo emergence of normal hematopoiesis 32, 35 in MDS and AML patients treated with low doses of DAC.
